International Journal of Science and Research Archive

eISSN: 2582-8185

Cross Ref DOI: 10.30574/ijsra

Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

Role of artificial intelligence in transforming pharmaceutical technology and its challenges

Guna Ranjan Kolli [1, *] and Prabhakar Orsu [2]

[1] *Veranova, Devens, 01434. M.A United States of America.*

[2] *GITAM School of Pharmacy, GITAM Deemed to be University, Visakhapatnam, 530045 Andhra Pradesh, India.*

International Journal of Science and Research Archive, 2024, 13(02), 1884–1889

Publication history: Received on 13 October 2024; revised on 30 November 2024; accepted on 03 December 2024

Article DOI: https://doi.org/10.30574/ijsra.2024.13.2.2270

Abstract

Artificial intelligence (AI) has emerged as a powerful tool in transforming drug discovery, formulation, and testing within the pharmaceutical industry. AI is transforming drug discovery by analyzing large-scale biological data, such as genomics and proteomics, to identify disease-related targets. One of the major benefits of AI in drug discovery is its possibility to reduce the costs of research and development (R&D). It can predict crucial aspects of drug behavior, such as pharmacodynamics (PD) and pharmacokinetics (PK) —how a drug works in the body and how the body responds to the drug. By analyzing real-world patient data, AI can help create personalized treatment plans, improving outcomes by tailoring drugs to individual patient profiles. It also plays a part in drug delivery optimization, including designing more efficient pharmaceutical dosage forms. AI can optimize manufacturing process, which enhance consistency, and quality control. While the possibilities for AI in drug discovery is vast, there are also challenges. One key issue is the need for high-quality, well-curated data. Despite the challenges, the investment in AI technologies in the pharmaceutical industry presents exciting opportunities. In summary, there is immense possibilities with AI holds to enhance drug development by improving efficiency, reducing costs, and enabling more personalized treatments. This review outlines the role of AI and current pharmaceutical challenges.

Keywords: Artificial intelligence; Genomics; Proteomics; Pharmacokinetics; Pharmacodynamics

1. Introduction

The pharmaceutical industry is in a leading position to address some of the most pressing global challenges, from infectious diseases to chronic health conditions. The rapid development of COVID-19 vaccines, for example, demonstrated how quickly the industry can innovate when there's an urgent need. This ability to adapt and innovate is crucial in today's environment, where new health threats- whether emerging diseases, antibiotic resistance, or chronic conditions- require novel solutions [1]. Innovation in the pharmaceutical industry is driven by advancements across multiple areas. R&D in this sector is not only focused on the discovery of new drugs but also on improving existing treatments, enhancing manufacturing processes, ensuring patient safety, and addressing the challenges of distribution and accessibility [2].

The application of AI in the pharmaceutical industry's supply chain operations is indeed a transformative development, offering numerous benefits that can revolutionize efficiency, reduce costs, and improve decision- making processes [3].

The integration of AI into clinical study design enables more efficient resource allocation, improving how trials are structured and executed. AI can analyze large volumes of data generated from multiple sources, such as patient records, lab results, and patient-reported outcomes, leading to smarter decision-making [4].

* Corresponding author: Kolli Guna Ranjan

1.1. Pharmaceutical Innovation and Industry Challenges

Pharmaceutical innovations encompass a broad spectrum, from small molecule drugs to biologics, with an emphasis on achieving stability and higher potency to address unmet medical needs. One of key objectives is to develop drug molecules which deliver optimal therapeutic benefits while minimizing side effects, ensuring their suitability for use in healthcare [5].

However, the pharmaceutical industry is grappling with significant challenges, particularly in assessing toxicity levels associated with new drugs. Toxicity concerns remain a critical area of research, as understanding and mitigating adverse effects is essential for the development of safe and effective treatments.

In addition to these safety concerns, there is a need for ongoing technological advancements to support the industry's ability to meet global healthcare demands. With an increasing focus on precision medicine, personalized therapies, and the emergence of complex diseases, the pharmaceutical industry must leverage cutting-edge technologies to continue advancing drug development and improving patient outcomes [6].

2. Role of Artificial intelligence

Small molecules continue to play an important role in the pharmaceutical industry and are favored in drug development, largely due to their simplicity in chemical synthesis, cost-effectiveness, and potential for creating stable, potent formulations. These evolving market dynamics are placing increasing economic pressure on companies to pursue greater innovation. Despite these challenges, the biomolecular drug industry continues to experience rapid growth, driven by the need to address issues related to the limited efficacy of small molecules, as well as the slow pace of research and innovation dissemination in this field [7].

Biomolecules, such as proteins and nucleic acids, are essential for various biological functions. Their function and stability are heavily influenced by their sequence (the arrangement of amino acids or nucleotides) and their spatial conformation (the three-dimensional shape they fold into). Proper folding is critical for their activity and effectiveness. Some biomolecules, like insulin and adalimumab, have been developed as therapeutic products with significant clinical applications [8].

Integration of cutting-edge technologies is of significance, for solving PK-related challenges in drug development [9]. AI and human collaboration are key in addressing the complexities of prediction, bias, and interpretation. While AI can process and analyze data on a scale beyond human capabilities, the nuanced judgment required to navigate the gray zones of interpretation and to identify and correct biases still heavily relies on human expertise and oversight.

2.1. Machine Learning Methodologies: Supervised vs. Unsupervised Learning

Artificial Intelligence (AI) depends on machine learning (ML) techniques, including portions of natural language processing (NLP) and deep learning. These techniques enable machines learning from data and make resolution or pattern-based predictions in that data. The learning process can be classified into two primary categories: supervised learning and unsupervised learning (Figure 1) [10]. In pharmaceutical product development, AI models are increasingly leveraged to optimize various stages of the process, from drug discovery to clinical trials.



Figure 1 Different AI based models for application in pharmaceuticals

2.1.1. Supervised AI Learning

Supervised learning is a powerful method for solving problems where both input and output data are available, and the goal is to learn a mapping from inputs to outputs. It is often contrasted with unsupervised learning, where the algorithm must find patterns in data without predefined labels [11]. Few applications in the pharmaceutical industry are:

- Predictive Maintenance and Quality Control: Predictive maintenance and quality control are complementary strategies that can be greatly enhanced with the use of digital technologies like data analytics, IoT and AI [12].
- Drug Design and Discovery: Supervised learning algorithms are indeed transforming the drug discovery process by helping to predict drug activity, ADMET properties, and toxicity, as well as by accelerating virtual screening and generating novel drug candidates [13].
- Detection of Adverse events: Supervised learning algorithms can significantly enhance the efficiency of pharmacovigilance efforts by automating detection and classification of adverse events. By leveraging labeled data— specifically, reports of adverse events (AEs) linked to drugs—supervised based learning models training can be done to recognize patterns and predict potential safety issues [14].
- Disease Prognosis and Diagnosis: Supervised learning models, when applied to disease diagnosis and prognosis, leverage labeled medical data to make informed predictions about patients' health. These models

offer a powerful tool for both diagnosis and prognosis, improving clinical decision-making and patient outcomes [15]. By combining some of these techniques with domain-specific expertise, supervised learning can significantly improve decision- making, reduce time to market, and help in the discovery of safer and more effective drugs.

2.1.2. Unsupervised AI Learning

Unsupervised learning plays an important role in situations where labeled data is scarce or unavailable, and it can provide a deep understanding into the structure and relationships within large datasets [16]. It enables researchers to explore complex datasets, uncover hidden patterns, and gain insights into drug discovery, patient stratification, and clinical outcomes without relying on labeled data. Few techniques are described:

- Association rule mining: particularly through algorithms like Apriori, plays a crucial role in analyzing relationships within large datasets. In pharmaceutical sector, it can be leveraged to uncover valuable insights related to drug interactions (DDIs), adverse events, and patterns of co-occurrence between medications and medical conditions [17].
- Clustering: is a powerful technique in pharmaceutical research, offering the potential to discover patterns, groupings, and hidden relationships in complex biological, chemical, and clinical datasets. By applying clustering, researchers can uncover new insights into drug development, disease progression, and patient care [18].
- Anomaly detection: plays a crucial role in the pharmaceutical industry, especially for identifying rare, unusual, or potentially harmful occurrences. In this context, the goal is to uncover hidden risks or irregularities that could indicate safety concerns, data quality issues, or even fraud [19]. Unsupervised learning is a powerful tool for uncovering hidden patterns in pharmaceutical data, but it is essential to integrate these techniques with domain knowledge, experimental validation, and robust analysis frameworks to ensure the reliability and relevance of the findings.

3. AI Tools Limitations

AI-based models offer significant advantages in drug discovery, including the ability to analyze vast datasets quickly, predict molecular interactions, and suggest potential drug candidates, they do have inherent limitations that must be addressed. Some of these limitations include:

- Bias and Generalization: If the data used to train an AI model is biased or unrepresentative, the model will likely reflect those biases. This could lead to the identification of drug candidates that are not effective or safe for all populations. Ensuring diversity in training datasets is essential to mitigate these risks [20].
- Lack of clinical expertise: AI algorithms, particularly those that rely on statistical frameworks, excel at identifying patterns and correlations within large datasets, but they may struggle with capturing the full complexity of individual patient scenarios. The challenge, then, is in developing AI models that are more adaptable, transparent, and capable of considering the wider spectrum of variables that influence healthcare outcomes [21].
- Lack of Interpretability: Many AI models, particularly deep learning, are viewed as "black boxes." This means it can be hard to understand how the model makes a specific decision or prediction. In drug discovery context, this is a significant limitation because scientists need to understand the underlying biology and mechanisms of action to refine drug candidates and ensure their safety [22].

Because of these limitations, AI should be used as a tool to complement traditional experimental methods rather than replace them entirely. Traditional methods, such as in vitro testing, animal studies, and clinical trials, provide the hands-on experimental evidence that AI models cannot replace. A more integrated approach would involve using AI to predict potential drug candidates or therapeutic targets, and then validating these predictions through experimental techniques. This combined approach can help to streamline the drug discovery process while reducing the risks associated with both AI models and traditional methods.

4. Overview of AI in Pharmaceutical Development

The promise of AI in pharmaceutical development is immense, but its full potential will only be realized once key challenges are addressed. Data quality is a foundational concern; AI systems rely heavily on high-quality, diverse, and well-curated datasets to make accurate predictions. If data is incomplete, biased, or inconsistent, AI models may produce unreliable results, which could hinder the drug development process or lead to suboptimal treatment outcomes.

Regulatory frameworks also present a significant hurdle. The pharmaceutical industry is highly regulated, and any AI-driven innovation must align with existing safety and efficacy standards. Regulatory bodies like the FDA or EMA will need to establish guidelines that both foster innovation and ensure patient safety. The evolving nature of AI may require new regulatory approaches that can accommodate the pace of technological advancement without compromising safety.

Ethical considerations are also critical, especially regarding algorithmic transparency, the potential for biases and data privacy in AI models. For ensuring that AI technologies are developed and deployed in a way that are accountable, transparent, and fair, it is essential to maintaining public trust and ensuring that these innovations benefit all patients equitably.

However, with continued investment in AI research, close collaboration between industry leaders, academic experts, and regulatory authorities, and a clear focus on ethical principles, AI has the potential to drastically speed up drug discovery process, optimize clinical trials, personalize treatments, and ultimately improve patient outcomes. It's a very exciting time for the pharmaceutical industry, but careful navigation of these challenges will be crucial for success.

5. Conclusion

AI is indeed a game-changer in the pharmaceutical sector, especially when it comes to drug delivery technologies. Its ability to process vast amounts of data, recognize patterns, and make predictive analyses has opened new possibilities for enhancing drug development and personalized medicine.

The integration of AI into drug delivery technologies offers a transformative approach to improving patient outcomes. It enhances drug efficacy, reduces side effects, and enables more personalized treatments. By optimizing pharmacokinetic models, refining drug formulations, and improving manufacturing processes, AI not only makes drug development faster and more cost-effective, but also improves safety and compliance, paving the way for more advanced therapies. As the pharmaceutical industry transitions into the era of AI-driven healthcare, the potential for improved outcomes and revolutionary advancements in drug delivery is immense.

Compliance with ethical standards

Disclosure of conflict of interest

The Authors do not have a conflict of interest, as all the information obtained from respondents are for research purpose only and there is no relationship with any party.

References

[1] Krikorian, G., & Torreele, E. (2021). We cannot win the access to medicines struggle using the same thinking that causes the chronic access crisis. Health and human rights, 23(1), 119.

[2] Chavda, V. P., Anand, K., & Apostolopoulos, V. (Eds.). (2023). Bioinformatics Tools for Pharmaceutical Drug Product Development. John Wiley & Sons.

[3] Sharma, R., Shishodia, A., Gunasekaran, A., Min, H., & Munim, Z. H. (2022). The role of artificial intelligence in supply chain management: mapping the territory. International Journal of Production Research, 60(24), 7527-7550.

[4] Deloitte Using-Ai-to-Accelerate-Clinical-Trials. [(accessed on 1 May 2023)]. Available online: https://www2.deloitte.com/us/en/blog/health-care-blog/2022/using-ai-to-accelerate- clinical-trials.html

[5] Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature reviews Drug discovery, 8(12), 959-968.

[6] Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. Drug discovery today, 24(3), 773-780.

[7] Dickherber, A., Morris, S. A., & Grodzinski, P. (2015). NCI investment in nanotechnology: achievements and challenges for the future. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 7(3), 251-265.

[8] Chavda, V. P., Anand, K., & Apostolopoulos, V. (Eds.). (2023). Bioinformatics Tools for Pharmaceutical Drug Product Development. John Wiley & Sons.

[9] Wise, J., Möller, A., Christie, D., Kalra, D., Brodsky, E., Georgieva, E., ... & Arlington, S. (2018). The positive impacts of real-world data on the challenges facing the evolution of biopharma. Drug discovery today, 23(4), 788-801.

[10] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023 Jul 10;15(7):1916.

[11] Sarker, I. H. (2022). AI-based modeling: techniques, applications and research issues towards automation, intelligent and smart systems. SN Computer Science, 3(2), 158.

[12] Kavasidis, I., Lallas, E., Gerogiannis, V. C., Charitou, T., & Karageorgos, A. (2023). Predictive maintenance in pharmaceutical manufacturing lines using deep transformers. Procedia Computer Science, 220, 576-583.

[13] Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine learning in drug discovery: a review. Artificial intelligence review, 55(3), 1947-1999.

[14] Chapman, A. B., Peterson, K. S., Alba, P. R., DuVall, S. L., & Patterson, O. V. (2019). Detecting adverse drug events with rapidly trained classification models. Drug safety, 42, 147-156.

[15] Kumar, Y., Koul, A., Singla, R., & Ijaz, M. F. (2023). Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. Journal of ambient intelligence and humanized computing, 14(7), 8459-8486.

[16] Chavda, V. P., Anand, K., & Apostolopoulos, V. (Eds.). (2023). Bioinformatics Tools for Pharmaceutical Drug Product Development. John Wiley & Sons.

[17] Noguchi, Y., Ueno, A., Otsubo, M., Katsuno, H., Sugita, I., Kanematsu, Y., ... & Teramachi, H. (2018). A new search method using association rule mining for drug-drug interaction based on spontaneous report system. Frontiers in pharmacology, 9, 197.

[18] Karim, M. R., Beyan, O., Zappa, A., Costa, I. G., Rebholz-Schuhmann, D., Cochez, M., & Decker, S. (2021).Deep learning-based clustering approaches for bioinformatics. Briefings in bioinformatics, 22(1), 393-415.

[19] Goldstein, M., & Uchida, S. (2016). A comparative evaluation of unsupervised anomaly detection algorithms for multivariate data. PloS one, 11(4), e0152173.

[20] Norori, N., Hu, Q., Aellen, F. M., Faraci, F. D., & Tzovara, A. (2021). Addressing bias in big data and AI for health care: A call for open science. Patterns, 2(10).

[21] Davenport, T., & Kalakota, R. (2019). The potential for artificial intelligence in healthcare. Future healthcare journal, 6(2), 94-98.

[22] Chavda, V. P., Anand, K., & Apostolopoulos, V. (Eds.). (2023). Bioinformatics Tools for Pharmaceutical Drug Product Development. John Wiley & Sons.